NYSE: KAPA · Life Sciences · 4 alerts · CIK 1962011
Share price
$0.4069Close, Nov 16
Market cap
$1.91M
Shares outstanding
4.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kairos Pharma, LTD. filings on SEC EDGAR ↗
Kairos Pharma, Ltd. reported a net loss of $5.03 million for the nine months ended September 30, 2026, compared to a $4.08 million loss in the prior year period. The company remains in the development stage with no revenue, and its cash position decreased to $3.13 million as of September 30, 2026, from $4.49 million at year-end 2025.
Kairos Pharma, Ltd. entered into a third amendment to its existing equity line of credit (ELOC) purchase agreement with Helena Global Investment Opportunities I Ltd. The amendment extends the company's option to use the ELOC for an additional year until December 31, 2028, and follows previous amendments that adjusted the purchase price to 97% of VWAP and shortened the pricing period.
Kairos Pharma reported positive interim efficacy data from its Phase 2 trial of ENV-105 (carotuximab) in combination with apalutamide for metastatic castration-resistant prostate cancer. The combination therapy demonstrated a statistically significant median progression-free survival of 17.7 months compared to 2 months for apalutamide alone (P=0.0008). Based on these results, the company has modified the trial protocol to enroll patients earlier in the disease progression and targets trial completion by Q4 2027.
Kairos Pharma, Ltd. issued a new investor presentation to be presented by CEO John Yu at the H.C. Wainwright 28th Annual Global Investment Conference in New York. The presentation provides an update on the company's clinical programs and activities.
Counterparty
H.C. Wainwright 28th Annual Global Investment Conference